Furthermore, gene expression–based molecular classification of GBM (8), epidermal growth factor receptor amplification (EGFR) (9) and CpG island methylator phenotype status have emerged as additional potential predictors of treatment response and outcome (10). The gene discussed is EGFR; the disease is glioblastoma.